Karyopharm Therapeutics Inc. (KPTI)

NASDAQ: KPTI · Real-Time Price · USD

2.000

+0.070 (3.63%)

At close: Aug 19, 2026, 4:00 PM EDT

1.980

-0.020 (-1.00%)

After-hours: Aug 19, 2026, 6:43 PM EDT

Karyopharm Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	146.62	146.07	145.24	146.03	157.07	209.82
Revenue Growth	6.81%	0.57%	-0.55%	-7.03%	-25.14%	94.12%
Cost of Revenue	126.99	131.57	149.24	143.69	153.88	3.4
Gross Profit	19.63	14.5	-4	2.34	3.2	206.42
Selling, General & Admin	101.98	105.21	115.44	131.88	145.4	143.85
Research & Development	-	-	-	-	-	160.84
Operating Expenses	101.98	105.21	115.44	131.88	145.4	304.69
Operating Income	-82.35	-90.71	-119.44	-129.54	-142.2	-98.27
Interest Expense	-49.32	-45.85	-37.42	-23.82	-25	-26.05
Interest & Investment Income	2.39	2.77	7.4	10.94	2.36	0.58
Other Non Operating Income (Expenses)	-33.13	0.15	28.4	-0.36	-0.08	-0.09
EBT Excluding Unusual Items	-162.41	-133.63	-121.07	-142.78	-164.92	-123.82
Other Unusual Items	-62.37	-62.37	44.7	-	-	-
Pretax Income	-224.77	-196	-76.37	-142.78	-164.92	-123.82
Income Tax Expense	-0.03	0.04	0.06	0.32	0.37	0.27
Net Income	-224.74	-196.04	-76.42	-143.1	-165.29	-124.09
Net Income to Common	-224.74	-196.04	-76.42	-143.1	-165.29	-124.09
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	19	11	8	8	5	5
Shares Outstanding (Diluted)	19	11	8	8	5	5
Shares Change	129.56%	29.33%	11.02%	39.54%	8.85%	4.41%
EPS (Basic)	-11.58	-17.93	-9.41	-18.79	-30.28	-24.75
EPS (Diluted)	-11.58	-17.93	-14.00	-18.79	-30.30	-24.75
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-65.35	-75.37	-127.63	-92.72	-149.67	-107.33
Free Cash Flow Per Share	-3.37	-6.89	-15.10	-12.18	-27.42	-21.40
Gross Margin	13.39%	9.93%	-2.76%	1.60%	2.04%	98.38%
Operating Margin	-56.16%	-62.10%	-82.24%	-88.71%	-90.53%	-46.84%
Profit Margin	-153.28%	-134.21%	-52.62%	-97.99%	-105.23%	-59.14%
Free Cash Flow Margin	-44.57%	-51.60%	-87.88%	-63.50%	-95.29%	-51.15%
EBITDA	-82.2	-90.41	-119.1	-129.01	-141.58	-97.48
EBITDA Margin	-56.06%	-61.90%	-82.01%	-88.34%	-90.14%	-46.46%
D&A For EBITDA	0.15	0.3	0.34	0.53	0.62	0.79
EBIT	-82.35	-90.71	-119.44	-129.54	-142.2	-98.27
EBIT Margin	-56.16%	-62.10%	-82.24%	-88.71%	-90.53%	-46.84%
Revenue as Reported	146.62	146.07	145.24	146.03	157.07	209.82

SEC Filings: 10-K · 10-Q